South Korean medical AI company Lunit and Canada-based research organisation CellCarta have partnered to integrate digital pathology AI into clinical trials.
The collaboration aims to integrate Lunit’s pathology solutions into CellCarta’s services, allowing pharmaceutical sponsors to adopt AI analysis in trial workflows.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is expected to expand access to the digital pathology AI suite, Lunit SCOPE, which provides insights into tumour biology.
Lunit’s platform uses haematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole slide images for analysis.
The insights can be used in identifying patients who may benefit from specific therapies and biomarker development, advancing precision drug development.
Lunit CEO Brandon Suh said: “We’re thrilled to partner with CellCarta, a trusted CRO with a strong global presence and impressive leadership in digital pathology real-world deployment.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This collaboration gives more clinical research teams a way to harness the power of AI in pathology, and we look forward to seeing its impact on trials and, ultimately, on patients.”
CellCarta is a contract research organisation (CRO) with College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories in North America, Europe, and Asia.
Both companies focus on immune phenotype analysis, with CellCarta leveraging IHC stains and Lunit employing AI analysis.
The partnership enables access to Lunit SCOPE IO within CellCarta’s clinical infrastructure.
Lunit’s AI solution quantifies tumour-infiltrating lymphocytes and classifies immune phenotypes from H&E images.
CellCarta digital pathology solutions director Yannick Waumans said: “As more biopharma companies turn to AI-powered pathology to streamline biomarker development and patient selection, the demand for scalable, clinically validated solutions is rapidly growing.
“Partnering with Lunit allows us to offer our clients a powerful and proven AI platform that integrates seamlessly into global clinical trial workflows.”
In July, Lunit announced a collaboration with Microsoft to help bring its AI-powered cancer detection diagnostics into clinical practice.
